Treatment and Outcomes of Clinical Bioprosthetic Valve Thrombosis After Surgical and Transcatheter Valve Replacement: A Narrative Review
Journal of Vascular Diseases · 2026-11-12 · 5 (6) · 50
DOI: 10.3390/jvd5060050 ↗Abstract
Clinically significant thrombosis of surgical and transcatheter biological valves is increasingly recognised, yet most reviews have concentrated on subclinical leaflet thrombosis after transcatheter aortic valve implantation. This narrative review examines treatment and outcomes after diagnosis of clinical bioprosthetic valve thrombosis in the aortic or mitral position, keeping asymptomatic hypoattenuated leaflet thickening separate. The evidence consists of 17 observational cohorts and case series, several of which overlap, include right-sided valves or use treatment response as part of the diagnosis; no randomised treatment trial has been reported. After anticoagulation, mainly with vitamin K antagonists, most studies reported haemodynamic improvement in most patients assessed, but endpoints and denominators varied; in one transcatheter registry, complete resolution was reported in 12 of 26 patients (46%), a figure that included two patients who were not anticoagulated. Recovery often took several months. Recurrence and bleeding estimates come mainly from one mixed-valve cohort that included right-sided prostheses: thrombosis recurred in 23% of initial responders, and major bleeding occurred in 12% of treated patients versus 2% of matched controls, an observational difference that cannot be attributed wholly to anticoagulation. Evidence for thrombolysis, redo surgery and transcatheter reintervention is limited to small series and case reports. The evidence supports confirming suspected thrombosis with transoesophageal echocardiography or four-dimensional computed tomography, starting a vitamin K antagonist in haemodynamically stable patients, referring unstable patients or those with persistent obstruction for a Heart Team decision, and individualising extended anticoagulation against bleeding risk. Direct oral anticoagulants are not established for clinical thrombosis, and the optimal duration of treatment is unknown.
EUVIMED